XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization StrategyGlobeNewsWire • 05/09/23
XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone PortfolioGlobeNewsWire • 03/30/23
XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization StrategyGlobeNewsWire • 03/09/23
XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 01/07/23
New Executive Leadership Team Appointed to Accelerate XOMA's Differentiated Royalty Monetization StrategyGlobeNewsWire • 01/04/23
XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by OrganonGlobeNewsWire • 11/22/22
XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational EventsGlobeNewsWire • 11/03/22
XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational EventsGlobeNewsWire • 08/04/22
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone PaymentGlobeNewsWire • 06/02/22
XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational EventsGlobeNewsWire • 05/05/22
XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational EventsGlobeNewsWire • 03/08/22
XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic CancerGlobeNewsWire • 11/04/21